Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 13/20 | 0.74 |
| ▸ | CRBN | Q96SW2 | 13/20 | 0.74 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | NAMPT | P43490 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744797 | 1.00 | DDB1 (0.74) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL20595415 | 1.00 | DDB1 (0.74) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL29947073 | 0.96 | DDB1 (0.72) | DDB1CRBNGPR119ALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL29947007 | 0.94 | DDB1 (0.67) | DDB1CRBNGPR119ALDH1A1LMNA | |
| SCHEMBL30830949 | 0.92 | DDB1 (0.64) | DDB1CRBNGPR119 | |
| SCHEMBL31091747 | 0.89 | DDB1 (0.65) | DDB1CRBNGPR119MAPT | |
| SCHEMBL24125697 | 0.85 | DDB1 (0.62) | DDB1CRBNGPR119MAPTNAMPT | |
| SCHEMBL23301516 | 0.85 | DDB1 (0.62) | DDB1CRBNGPR119MAPTNAMPT | |
| SCHEMBL24125822 | 0.85 | DDB1 (0.62) | DDB1CRBNGPR119MAPTNAMPT | |
| SCHEMBL30258220 | 0.85 | DDB1 (0.64) | DDB1CRBNGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4717317-A2 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 Therapeutics, Inc. (US) | 2026-04-01 | — | — | EP | disclosed |
| US-12559492-B2 | BRAF degraders | C4 THERAPEUTICS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3641762-B1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2026-02-12 | — | — | US | disclosed |
| EP-4681715-A2 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2026-01-15 | — | — | US | disclosed |
| EP-4076450-B1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS INC (US) | 2025-12-10 | — | — | EP | disclosed |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | C4 THERAPEUTICS, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2025-08-28 | — | — | US | disclosed |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2023283372-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF IRAK4 PROTEINS | BIOGEN MA INC. (US) | 2023-01-12 | — | — | WO | disclosed |
| US-11459335-B2 | N/O-linked Degrons and Degronimers for protein degradation | C4 THERAPEUTICS, INC. (US) | 2022-10-04 | — | — | US | disclosed |
| CN-114901277-A | Isoindolinone and indazole compounds for EGFR degradation | C4医药公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2021255212-A1 | BRAF DEGRADERS | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-23 | — | — | WO | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127561-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | C4 THERAPEUTICS, INC. (US) | 2021-06-24 | — | — | WO | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2020-05-07 | — | — | US | disclosed |
| CN-110769822-A | N/O-linked degron and degron bodies for protein degradation | C4医药公司 | 2020-02-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12441740-B2 | N/O-linked degrons and degronimers for protein degradation | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885GPR119 2204/4885 |
| US-12559492-B2 | BRAF degraders | BRAF, NRAS, HRAS | DDB1 425/4885CRBN 32/4885GPR119 1556/4885 |
| US-20260015362-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBLC, CBL | DDB1 365/4885CRBN 1/4885GPR119 1441/4885 |
| US-12486290-B2 | Isoindolinone and indazole compounds for the degradation of EGFR | EGFR, ERBB2, ERBB3 | DDB1 576/4885CRBN 75/4885GPR119 3602/4885 |
| US-20230110648-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DDB1 576/4885CRBN 75/4885GPR119 3602/4885 |
| US-20250270234-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DDB1 576/4885CRBN 75/4885GPR119 3602/4885 |
| US-20260042782-A1 | ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFR | EGFR, ERBB2, ERBB3 | DDB1 823/4885CRBN 25/4885GPR119 3950/4885 |
| US-11459335-B2 | N/O-linked Degrons and Degronimers for protein degradation | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885GPR119 2204/4885 |
| US-20200140456-A1 | N/O-LINKED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION | CRBN, CBL, STUB1 | DDB1 319/4885CRBN 1/4885GPR119 2204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.